National Bank of Canada FI Has $49.16 Million Stake in Boston Scientific Co. (NYSE:BSX)

National Bank of Canada FI boosted its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 60.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 850,070 shares of the medical equipment provider's stock after acquiring an additional 319,376 shares during the quarter. National Bank of Canada FI owned 0.06% of Boston Scientific worth $49,163,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. FMR LLC increased its holdings in Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider's stock valued at $6,648,595,000 after buying an additional 8,045,263 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of Boston Scientific by 391.6% in the 3rd quarter. American Century Companies Inc. now owns 3,271,810 shares of the medical equipment provider's stock valued at $172,752,000 after acquiring an additional 2,606,253 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider's stock worth $2,221,641,000 after acquiring an additional 2,336,348 shares in the last quarter. Winslow Capital Management LLC lifted its stake in Boston Scientific by 39.3% during the third quarter. Winslow Capital Management LLC now owns 6,129,573 shares of the medical equipment provider's stock worth $323,641,000 after purchasing an additional 1,730,133 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Boston Scientific by 1.2% in the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider's stock valued at $6,534,969,000 after purchasing an additional 1,525,432 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Price Performance

BSX stock traded down $0.30 during trading on Monday, reaching $72.55. 4,922,822 shares of the company were exchanged, compared to its average volume of 6,641,671. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $74.39. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The company has a market cap of $106.44 billion, a P/E ratio of 60.97, a PEG ratio of 2.51 and a beta of 0.77. The stock's 50 day moving average price is $68.54 and its 200 day moving average price is $61.57.

Analysts Set New Price Targets

Several analysts have recently weighed in on BSX shares. Raymond James boosted their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a "strong-buy" rating in a research report on Thursday, April 25th. Citigroup upped their price objective on shares of Boston Scientific from $79.00 to $85.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their target price on Boston Scientific from $63.00 to $73.00 and gave the stock a "hold" rating in a research report on Thursday, April 25th. Mizuho upped their target price on Boston Scientific from $80.00 to $85.00 and gave the company a "buy" rating in a research report on Thursday, April 25th. Finally, UBS Group lifted their price target on Boston Scientific from $74.00 to $90.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $75.09.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, EVP John Bradley Sorenson sold 17,587 shares of the company's stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $71.50, for a total value of $1,257,470.50. Following the sale, the executive vice president now directly owns 50,638 shares in the company, valued at $3,620,617. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company's stock, valued at approximately $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock worth $5,395,560 in the last quarter. Company insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.